Jaydess (Levonorgestrel)

Jaydess (levonorgestrel) acts within the hormonal contraceptive pathway to prevent pregnancy and to treat menstrual bleeding disorders.

• Contraception: provides long‑term, reversible birth control for up to three years.
• Heavy menstrual bleeding: reduces menstrual blood loss and improves anemia associated with excessive bleeding.
• Long‑term reversible contraception: offers a convenient, low‑maintenance option without daily dosing.

• Levonorgestrel released from the intrauterine system diffuses locally into the endometrium and cervical mucus. It binds to progesterone receptors, causing thickening of cervical mucus, inhibition of endometrial proliferation, and, in some users, suppression of ovulation. The device releases a constant low dose of 13.5 µg per day, maintaining effective tissue concentrations while minimizing systemic exposure.

Levonorgestrel delivered via the intrauterine system may be associated with a range of adverse reactions.

Common Side Effects

• Irregular bleeding or spotting: unpredictable menstrual bleeding patterns, especially during the first months.
• Amenorrhea: absence of menstrual periods after prolonged use.
• Headache: mild to moderate tension‑type headaches.
• Breast tenderness: transient discomfort or swelling of the breasts.

Serious or Rare Side Effects

• Pelvic inflammatory disease: infection that can affect the uterus, fallopian tubes, or ovaries.
• Uterine perforation: rare event where the IUS breaches the uterine wall during insertion.
• Ectopic pregnancy: pregnancy occurring outside the uterus, most commonly in the fallopian tube.

Before prescribing Jaydess, clinicians should consider several precautionary measures to ensure patient safety.

• Contraindications: avoid use in women with active pelvic infection, unexplained vaginal bleeding, or known uterine anomalies.
• Pregnancy testing: confirm the patient is not pregnant before insertion.
• Follow‑up: schedule a check‑up 4–6 weeks after insertion to verify correct placement.
• Medication interactions: be aware that enzyme‑inducing drugs may reduce efficacy.
• Breastfeeding: discuss potential risks if the patient plans to breastfeed.
• Store at ambient temperature: keep the device in its original packaging, protect from moisture and direct sunlight, and store below 25 °C.

Levonorgestrel released from an intrauterine system can interact with other medicines that affect hormone metabolism or uterine environment.

Major Interactions (Avoid)

• Rifampicin and other strong enzyme inducers: may markedly lower levonorgestrel levels, reducing contraceptive effectiveness.
• Antiepileptic drugs (e.g., carbamazepine, phenytoin): can increase hormone metabolism and compromise efficacy.
• Antiretroviral therapy (e.g., efavirenz): may reduce levonorgestrel concentrations.

Moderate Interactions (Monitor Closely)

• Hormonal therapies (e.g., estrogen‑containing contraceptives): may alter bleeding patterns when used concurrently.
• NSAIDs: can increase the risk of breakthrough bleeding.
• Antifungal azoles (e.g., ketoconazole): may modestly affect levonorgestrel metabolism.